PROVIT The Influence of Probiotics on Body and Mind in Individuals With Psychiatric Disorders

Depression Clinical Trial

Official title:

The Influence of Probiotics on Body and Mind in Individuals With Psychiatric Disorders - a Clinical Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03300440
• Other study ID #: 29-235 ex 16/17
• Status: Active, not recruiting
• Phase: N/A
• Start date: June 21, 2017
• Est. completion date: June 2019

Study information

• Verified date: September 2018
• Source: Medical University of Graz
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to explore the effects of probiotics in individuals with a clinically relevant depression on psychiatric symptoms and cognition, inflammatory parameters, as well as gene-expression. The study is conducted as a placebo-controlled, randomized, double-blind, prospective, monocentric clinical study, with a two-arm parallel group design. Individuals in the intervention group receive the multispecies probiotics "Omnibiotics Stress Repair" in addition to vitamin B7, while individuals in the control group receive "Placebo" in addition to vitamin B7.

Description:

The study takes places at the Medical University of Graz, Department of Psychiatry and Psychotherapeutic Medicine. Individuals that start inpatient treatment at the ward in the first floor of the Department because of a major depressive episode are eligible. After inclusion into the study, the participants are asked to fill in different self-rating questionnaires (Becks-Depression Inventory-II BDI-II, Symptom Checklist-90-Revised SCL-90-R, Manie-Selbstbeurteilungsskala german adaptation of Self-Report manic inventory (SRMI) - MSS, food frequency questionnaire). General data are explored routinely, as well as a diagnostic interview (MINI - mini international neuropsychiatric interview, German version 5.0) is performed during the stay at the hospital. Participants are asked to provide a stool probe as soon as possible.

At the day after admission, fasting blood is taken (100ml). Routine parameters are further analyzed at the local laboratory, while the rest is stored at -80 degree for later analyzes. Afterwards a cognitive test-battery is performed to measure verbal learning and memory, information processing speed, cognitive flexibility and working memory capacity.

After one week a further stool probe is taken, to measure possible changes in dietary habits due to the stay at the hospital. Antidepressive treatment at the hospital is continued as treatment as usual.

At the end participants go through a similar cognitive test battery as at the beginning and are asked to fill in the same self-rating questionnaires. If participants are discharged before day 28 they are given their own preparation and instructed to take it at home in the exact same manner. An outpatient appointment at the end of the preparation intake is arranged to collect the fasting blood and stool sample and to perform the cognitive assessment.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 80
• Est. completion date: June 2019
• Est. primary completion date: August 1, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• diagnosis of mood (affective) disorders (ICD 10 F3xx)

• or neurotic, stress-related and somatoform disorders (ICD 10 F4xx),

• inpatient treatment at the ward in the first floor of the Department of Psychiatry and Psychotherapeutic Medicine in Graz

• written informed consent

Exclusion Criteria:

• acute suicidality and potential dangers for themselves or other persons

• intake of antibiotics during the last month

• intake of food supplement with probiotic cultures or butyrate during the last year

• persons who are incapable of giving consent

• dementia (Mini Mental Status Examination = 20)

• mental retardation

• misuse of laxatives and diuretics

• acute or chronical gastrointestinal infection or diseases

• pregnancy or breastfeeding period

• acute tumor or autoimmune diseases

• organic brain/mental disorders

• active drug or alcohol abuse

Related Conditions & MeSH terms

• Depression
• Disease
• Mental Disorders
• Mood Disorders
• Problem Behavior

Intervention

Dietary Supplement:
• Probiotics and vitamin B7
Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form (7,5 x 109 CFU) Bacteria strains: Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Bifidobacterium lactis W52 Lactobacillus acidophilus W22 Lactobacillus casei W56 Lactobacillus paracasei W20 Lactobacillus plantarum W62 Lactobacillus salivarius W24 Lactococcus lactis W19 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes
• Placebo and vitamin B7
Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes

Locations

Country	Name	City	State
Austria	Medical University of Graz, Department of Psychiatry and Psychotherapeutic Medicine	Graz	Styria

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Graz

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in fecal butyrate levels [µmol/g]	Stool diagnostics is performed by Biovis	28 (+/- 2) days
Primary	Changes in fecal zonulin levels [ng/ml]	Stool diagnostics is performed by Biovis	28 (+/- 2) days
Primary	Changes in gastrointestinal quality of life [total score]	Gastrointestinal quality of life index (Eypasch E, Wood-Dauphinée S, Williams JI, et al. The Gastrointestinal Quality of Life Index. A clinical index for measuring patient status in gastroenterologic surgery. Chirurg. 1993;64(4):264-274.)	28 (+/- 2) days
Primary	Changes in depressive symptoms [HAM-D - total score]	Clinical assessment of Hamilton Rating Scale for Depression (Hamilton, M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry. 1960;23: 56-62)	28 (+/- 2) days
Primary	Changes in depressive symptoms [BDI-II - total score]	Self-rating of depressive symptoms by the patient with Beck Depression Inventory-II (Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. Journal of Personality Assessment. 1996;67 (3): 588-97.)	28 (+/- 2) days
Primary	Changes in overall psychological distress [SCL-90-R9 - GSI]	GSI - global severity index of Symptom Checklist-90-Revised (Franke, GH. SCL-90-R. Die Symptom-Checkliste von Derogatis-Deutsche Version. Göttingen: Beltz, 1995.)	28 (+/- 2) days